Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec 25;19(1):58.
doi: 10.3390/ijms19010058.

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis

Lluís Puig  1
Affiliations
Review

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis

Lluís Puig. Int J Mol Sci. .

Abstract

There is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic inflammation, with shared pathways and cytokines common to metabolic syndrome, atherosclerosis and psoriasis, might provide the basis for the cardiovascular and metabolic comorbidities of psoriasis and PsA. The purpose of this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of cardiovascular risk factors and cardiovascular disease in patients with psoriasis and/or PsA; the use of analytical determinations, physiologic measures and imaging techniques as surrogate biomarkers of atherosclerosis, endothelial dysfunction and cardiovascular disease in these patients; and the epidemiological and clinical data, including results of clinical trials, supporting a cardioprotective role of anti-inflammatory and disease-modifying treatment in psoriasis and PsA.

Keywords: atherosclerosis; cardiovascular disease; cardiovascular risk; inflammation; metabolic syndrome; psoriasis; psoriatic arthritis.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

References

    1. Hawkes J.E., Chan T.C., Krueger J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J. Allergy Clin. Immunol. 2017;140:645–653. doi: 10.1016/j.jaci.2017.07.004. - DOI - PMC - PubMed
    1. Davidovici B.B., Sattar N., Prinz J., Puig L., Emery P., Barker J.N., van de Kerkhof P., Ståhle M., Nestle F.O., Girolomoni G., et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J. Investig. Dermatol. 2010;130:1785–1796. doi: 10.1038/jid.2010.103. - DOI - PubMed
    1. Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The ‘psoriatic march’: A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp. Dermatol. 2011;20:303–307. doi: 10.1111/j.1600-0625.2011.01261.x. - DOI - PubMed
    1. Takeshita J., Grewal S., Langan S.M., Mehta N.N., Ogdie A., Van Voorhees A.S., Gelfand J.M. Psoriasis and comorbid diseases: Implications for management. J. Am. Acad. Dermatol. 2017;76:393–403. doi: 10.1016/j.jaad.2016.07.065. - DOI - PMC - PubMed
    1. Gupta Y., Moller S., Zillikens D., Boehncke W.H., Ibrahim S.M., Ludwig R.J. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease. Exp. Dermatol. 2013;22:552–553. doi: 10.1111/exd.12192. - DOI - PubMed